Literature DB >> 21999180

The clinical stage of allergic rhinitis is correlated to inflammation as detected by nasal cytology.

Matteo Gelardi1, Cristoforo Incorvaia, Maria Luisa Fiorella, Paolo Petrone, Nicola Quaranta, Cosimo Russo, Paola Puccinelli, Ilaria Dell'Albani, Gian Galeazzo Riario-Sforza, Eleonora Cattaneo, Gianni Passalacqua, Franco Frati.   

Abstract

Allergic rhinitis (AR) is the most common allergic disease. The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines classify AR according to its duration and severity and suggest recommended treatments, but there is evidence that these guidelines are insufficiently followed. Considering the validity of histopathological data, physicians are more likely to be persuaded by such information on AR. Thus, we attempted to define the severity of AR by nasal cytology on the basis of the ARIA classification. We examined 64 patients with AR caused by sensitization to grass pollen. We clinically defined AR according to the ARIA classification and performed nasal cytology by Rhino-probe sampling, staining and reading by optical microscopic observation. Clinically, 22 (34.4%), 21 (32.8%), 10 (15.6%), and 11 (17.2%) patients had mild intermittent, moderate-to-severe intermittent, mild persistent, and moderate-to-severe persistent AR, respectively. Nasal cytology detected neutrophils in 49 patients, eosinophils in 41 patients, mast cells in 21 patients, and lymphocytes or plasma cells in 28 patients. The patients with moderate-to-severe AR had significantly more mast cells and lymphocytes/ plasma cells than those with mild AR. Our findings demonstrate that the ARIA classification of AR severity is associated with different cell counts in nasal cytology; especially, moderate-to-severe AR shows significantly increased counts of mast cells and lymphocyte or plasma cells. The ease of performing nasal cytology ensures is feasibility as an office AR diagnostic procedure for primary care physicians, able to indicate when anti-inflammatory treatments, such as intranasal corticosteroids and subcutaneous or sublingual allergen immunotherapy, are needed.

Entities:  

Mesh:

Year:  2011        PMID: 21999180     DOI: 10.2174/187152811798104917

Source DB:  PubMed          Journal:  Inflamm Allergy Drug Targets        ISSN: 1871-5281


  6 in total

1.  The normative value of inflammatory cells in the nasal perfusate of Chinese adults: a pilot study.

Authors:  Yong Zhang; Qiuping Wang; Yanqing Xie; Zhiyi Wang; Derong Li; Li Ma; Xinju Pang; Weidong Yu; Nanshan Zhong
Journal:  J Thorac Dis       Date:  2014-07       Impact factor: 2.895

2.  The association of allergic rhinitis severity with neutrophil-lymphocyte and platelet-lymphocyte ratio in adults.

Authors:  Ayşe Enise Göker; Enis Ekincioglu; Maide Hacer Alagöz; Ruslan Hummatov; Melis E Arkan; Ayca Baskadem Yilmazer; Arzu Güngör Doğuşlu; Yavuz Uyar
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-09-20       Impact factor: 2.503

3.  Is neutrophil-lymphocyte ratio associated with the severity of allergic rhinitis in children?

Authors:  Mahmut Dogru; Muhammed Fatih Evcimik; Ahmet Adnan Cirik
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-11-02       Impact factor: 2.503

4.  Seasonal changes in nasal cytology in mite-allergic patients.

Authors:  Matteo Gelardi; Diego G Peroni; Cristoforo Incorvaia; Nicola Quaranta; Concetta De Luca; Salvatore Barberi; Ilaria Dell'albani; Massimo Landi; Franco Frati; Olivier de Beaumont
Journal:  J Inflamm Res       Date:  2014-03-28

5.  A survey of clinical features of allergic rhinitis in adults.

Authors:  Franco Frati; Ilaria Dell'Albani; Giovanni Passalacqua; Sergio Bonini; Oliviero Rossi; Gianenrico Senna; Cristoforo Incorvaia
Journal:  Med Sci Monit       Date:  2014-11-04

6.  In children allergic to ragweed pollen, nasal inflammation is not influenced by monosensitization or polysensitization.

Authors:  Matteo Gelardi; Mariangela Bosoni; Marco Morelli; Silvia Beretta; Cristoforo Incorvaia; Serena Buttafava; Massimo Landi; Simonetta Masieri; Franco Frati; Nicola Quaranta; Gian Vincenzo Zuccotti
Journal:  J Inflamm Res       Date:  2016-04-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.